Artificial Intelligence for solid tumor diagnosis in digital pathology

Author(s):  
Christophe Klein ◽  
Qinghe Zeng ◽  
Floriane Arbaretaz ◽  
Estelle Devêvre ◽  
Julien Calderaro ◽  
...  
Healthcare ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 30
Author(s):  
Daniele Giansanti

Thanks to the incredible changes promoted by Information and Communication Technology (ICT) conveyed today by electronic-health (eHealth) and mobile-health (mHealth), many new applications of both organ and cellular diagnostics are now possible [...]


2021 ◽  
Author(s):  
Changjiang Zhou ◽  
Xiaobing Feng ◽  
Hongbin Cai ◽  
Yi Jin ◽  
Harvest F. Gu ◽  
...  

2018 ◽  
Vol 12 (11) ◽  
pp. 1197-1201
Author(s):  
Demosthenes E Ziogas ◽  
Ioannis D Kyrochristos ◽  
Efstathios G Lykoudis ◽  
Dimitrios H Roukos

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A874-A874
Author(s):  
David Soong ◽  
David Soong ◽  
David Soong ◽  
Anantharaman Muthuswamy ◽  
Clifton Drew ◽  
...  

BackgroundRecent advances in machine learning and digital pathology have enabled a variety of applications including predicting tumor grade and genetic subtypes, quantifying the tumor microenvironment (TME), and identifying prognostic morphological features from H&E whole slide images (WSI). These supervised deep learning models require large quantities of images manually annotated with cellular- and tissue-level details by pathologists, which limits scale and generalizability across cancer types and imaging platforms. Here we propose a semi-supervised deep learning framework that automatically annotates biologically relevant image content from hundreds of solid tumor WSI with minimal pathologist intervention, thus improving quality and speed of analytical workflows aimed at deriving clinically relevant features.MethodsThe dataset consisted of >200 H&E images across >10 solid tumor types (e.g. breast, lung, colorectal, cervical, and urothelial cancers) from advanced disease patients. WSI were first partitioned into small tiles of 128μm for feature extraction using a 50-layer convolutional neural network pre-trained on the ImageNet database. Dimensionality reduction and unsupervised clustering were applied to the resultant embeddings and image clusters were identified with enriched histological and morphological characteristics. A random subset of representative tiles (<0.5% of whole slide tissue areas) from these distinct image clusters was manually reviewed by pathologists and assigned to eight histological and morphological categories: tumor, stroma/connective tissue, necrotic cells, lymphocytes, red blood cells, white blood cells, normal tissue and glass/background. This dataset allowed the development of a multi-label deep neural network to segment morphologically distinct regions and detect/quantify histopathological features in WSI.ResultsAs representative image tiles within each image cluster were morphologically similar, expert pathologists were able to assign annotations to multiple images in parallel, effectively at 150 images/hour. Five-fold cross-validation showed average prediction accuracy of 0.93 [0.8–1.0] and area under the curve of 0.90 [0.8–1.0] over the eight image categories. As an extension of this classifier framework, all whole slide H&E images were segmented and composite lymphocyte, stromal, and necrotic content per patient tumor was derived and correlated with estimates by pathologists (p<0.05).ConclusionsA novel and scalable deep learning framework for annotating and learning H&E features from a large unlabeled WSI dataset across tumor types was developed. This automated approach accurately identified distinct histomorphological features, with significantly reduced labeling time and effort required for pathologists. Further, this classifier framework was extended to annotate regions enriched in lymphocytes, stromal, and necrotic cells – important TME contexture with clinical relevance for patient prognosis and treatment decisions.


2021 ◽  
pp. jclinpath-2020-207351
Author(s):  
Jenny Fitzgerald ◽  
Debra Higgins ◽  
Claudia Mazo Vargas ◽  
William Watson ◽  
Catherine Mooney ◽  
...  

Clinical workflows in oncology depend on predictive and prognostic biomarkers. However, the growing number of complex biomarkers contributes to costly and delayed decision-making in routine oncology care and treatment. As cancer is expected to rank as the leading cause of death and the single most important barrier to increasing life expectancy in the 21st century, there is a major emphasis on precision medicine, particularly individualisation of treatment through better prediction of patient outcome. Over the past few years, both surgical and pathology specialties have suffered cutbacks and a low uptake of pathology specialists means a solution is required to enable high-throughput screening and personalised treatment in this area to alleviate bottlenecks. Digital imaging in pathology has undergone an exponential period of growth. Deep-learning (DL) platforms for hematoxylin and eosin (H&E) image analysis, with preliminary artificial intelligence (AI)-based grading capabilities of specimens, can evaluate image characteristics which may not be visually apparent to a pathologist and offer new possibilities for better modelling of disease appearance and possibly improve the prediction of disease stage and patient outcome. Although digital pathology and AI are still emerging areas, they are the critical components for advancing personalised medicine. Integration of transcriptomic analysis, clinical information and AI-based image analysis is yet an uncultivated field by which healthcare professionals can make improved treatment decisions in cancer. This short review describes the potential application of integrative AI in offering better detection, quantification, classification, prognosis and prediction of breast and prostate cancer and also highlights the utilisation of machine learning systems in biomarker evaluation.


2020 ◽  
pp. 367-382 ◽  
Author(s):  
Stephanie A. Harmon ◽  
Thomas H. Sanford ◽  
G. Thomas Brown ◽  
Chris Yang ◽  
Sherif Mehralivand ◽  
...  

PURPOSE To develop an artificial intelligence (AI)–based model for identifying patients with lymph node (LN) metastasis based on digital evaluation of primary tumors and train the model using cystectomy specimens available from The Cancer Genome Atlas (TCGA) Project; patients from our institution were included for validation of the leave-out test cohort. METHODS In all, 307 patients were identified for inclusion in the study (TCGA, n = 294; in-house, n = 13). Deep learning models were trained from image patches at 2.5×, 5×, 10×, and 20× magnifications, and spatially resolved prediction maps were combined with microenvironment (lymphocyte infiltration) features to derive a final patient-level AI score (probability of LN metastasis). Training and validation included 219 patients (training, n = 146; validation, n = 73); 89 patients (TCGA, n = 75; in-house, n = 13) were reserved as an independent testing set. Multivariable logistic regression models for predicting LN status based on clinicopathologic features alone and a combined model with AI score were fit to training and validation sets. RESULTS Several patients were determined to have positive LN metastasis in TCGA (n = 105; 35.7%) and in-house (n = 3; 23.1%) cohorts. A clinicopathologic model that considered using factors such as age, T stage, and lymphovascular invasion demonstrated an area under the curve (AUC) of 0.755 (95% CI, 0.680 to 0.831) in the training and validation cohorts compared with the cross validation of the AI score (likelihood of positive LNs), which achieved an AUC of 0.866 (95% CI, 0.812 to 0.920; P = .021). Performance in the test cohort was similar, with a clinicopathologic model AUC of 0.678 (95% CI, 0.554 to 0.802) and an AI score of 0.784 (95% CI, 0.702 to 0.896; P = .21). In addition, the AI score remained significant after adjusting for clinicopathologic variables ( P = 1.08 × 10−9), and the combined model significantly outperformed clinicopathologic features alone in the test cohort with an AUC of 0.807 (95% CI, 0.702 to 0.912; P = .047). CONCLUSION Patients who are at higher risk of having positive LNs during cystectomy can be identified on primary tumor samples using novel AI-based methodologies applied to digital hematoxylin and eosin–stained slides.


2020 ◽  
pp. jclinpath-2020-206715
Author(s):  
Nikolaos Stathonikos ◽  
Tri Q Nguyen ◽  
Paul J van Diest

Since 2007, we have gradually been building up infrastructure for digital pathology, starting with a whole slide scanner park to build up a digital archive to streamline doing multidisciplinary meetings, student teaching and research, culminating in a full digital diagnostic workflow where we are currently integrating artificial intelligence algorithms. In this paper, we highlight the different steps in this process towards digital diagnostics, which was at times a rocky road with definitely issues in implementation, but eventually an exciting new way to practice pathology in a more modern and efficient way where patient safety has clearly gone up.


2019 ◽  
Vol 20 (5) ◽  
pp. e253-e261 ◽  
Author(s):  
Muhammad Khalid Khan Niazi ◽  
Anil V Parwani ◽  
Metin N Gurcan

2021 ◽  
Vol 2 (2) ◽  
pp. 12-24
Author(s):  
Ying Shao ◽  
Yu-Xuan Zhang ◽  
Huan-Huan Chen ◽  
Shan-Shan Lu ◽  
Shi-Chang Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document